Sapphire Star Partners LP Raises Stake in Sinovac Biotech Ltd. (SVA)

Share on StockTwits

Sapphire Star Partners LP raised its holdings in shares of Sinovac Biotech Ltd. (NASDAQ:SVA) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,014 shares of the biopharmaceutical company’s stock after purchasing an additional 3,294 shares during the period. Sapphire Star Partners LP owned 0.18% of Sinovac Biotech worth $722,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in SVA. Vivo Capital LLC acquired a new stake in Sinovac Biotech during the 3rd quarter worth approximately $44,958,000. Seizert Capital Partners LLC acquired a new stake in Sinovac Biotech during the 3rd quarter worth approximately $275,000. Finally, Ramsey Quantitative Systems acquired a new stake in Sinovac Biotech during the 4th quarter worth approximately $84,000. Institutional investors own 21.38% of the company’s stock.

Shares of SVA remained flat at $$6.47 during mid-day trading on Monday. Sinovac Biotech Ltd. has a 12 month low of $5.73 and a 12 month high of $8.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 2.28.

Separately, BidaskClub cut shares of Sinovac Biotech from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th.

COPYRIGHT VIOLATION WARNING: This news story was reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/11/sapphire-star-partners-lp-boosts-stake-in-sinovac-biotech-ltd-sva.html.

About Sinovac Biotech

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases.

Read More: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply